Re-irradiation for Recurrent Glioblastoma: a Pattern of Care Analysis

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2024 Nov 26

PMID 39587462

Authors

Susanne Rogers

Markus Gross

Ekin Ermis

Gizem Cosgun

Brigitta G Baumert

Thomas Mader

Christina Schroeder

Nicoletta Lomax

Sara Alonso

Adela Ademaj

Tessa Lazeroms

Seok-Yun Lee

Michael Mayinger

Christoph Mamot

Lucia Schwyzer

Gerrit A Schubert

Oliver Riesterer

Affiliations

Soon will be listed here.

Abstract

Background: 90% of glioblastomas (GBM) relapse within two years of diagnosis. In contrast to the initial setting, there is no standard management for recurrent disease and options include hypofractionated stereotactic re-irradiation (re-mHSRT). The aims of this study were to investigate re-mHSRT practice in Swiss neuro-oncology centres.

Methods: A survey of 18 questions regarding re-irradiation for GBM was created and distributed electronically (SurveyMonkey, USA) to 11 radiation oncologists in Switzerland specialising in brain tumours. We evaluated the clinical outcomes of a multicentre series of patients treated with an established re-mHSRT schedule to benchmark these against the literature and investigated the radiological patterns of relapse after re-mHSRT.

Results: 8 of 11 (73%) radiation oncologists responded to the survey and re-irradiation practice was heterogeneous. The 10 × 3.5 Gy schedule (RTOG 1205, BRIOChe trials) was used by 5/8 respondents and 47/50 patients with recurrent GBM treated with re-mHSRT with this schedule in daily practice were included in the analysis. The median time to re-mHSRT following completion of adjuvant RT was 23.3 (7-224) months. The median PTV at re-mHSRT was 22.0 cm (0.9-190). Combined CTV + PTV margins ranged from 0 to 10 mm and median prescription isodose was 80% (67-100). 14/47 (30%) patients received temozolomide and four (8.5%) continued bevacizumab concomitantly. On multivariable analysis, concomitant systemic therapy predicted for progression-free survival (PFS), HR 2.87 (95% CI 1-03-7.96), p = 0.042. Median PFS following re-mHSRT was 6.6 (0.2-92.5) months and 26/47 patients (55%) received subsequent systemic therapy. The median overall survival (OS) following recurrence was 11.8 months (1.5-92.5), similar to the 10.8 months in the literature with the same schedule. The six-month OS rate was 37/47 (79%), which compares well with the 73% reported in a meta-analysis of 50 publications employing various schedules. In a subgroup analysis of 36/47 (79%) patients with MR follow-up after re-mHSRT, 8/36 (22%) had no radiological evidence of tumour progression at a median follow-up of 9.4 months. 21/28 (75%) radiological relapses were in-field, two were marginal and five were out of field.

Conclusions: Re-mHSRT with 10 × 3.5 Gy can achieve local control in selected patients with recurrent GBM.

References

McBain C, Lawrie T, Rogozinska E, Kernohan A, Robinson T, Jefferies S . Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021; 5:CD013579. PMC: 8121043. DOI: 10.1002/14651858.CD013579.pub2. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

Cuneo K, Vredenburgh J, Sampson J, Reardon D, Desjardins A, Peters K . Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2011; 82(5):2018-24. PMC: 3690566. DOI: 10.1016/j.ijrobp.2010.12.074. View

Kessel K, Hesse J, Straube C, Zimmer C, Schmidt-Graf F, Schlegel J . Modification and optimization of an established prognostic score after re-irradiation of recurrent glioma. PLoS One. 2017; 12(7):e0180457. PMC: 5498044. DOI: 10.1371/journal.pone.0180457. View

Lee S, Fraass B, Marsh L, Herbort K, Gebarski S, Martel M . Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999; 43(1):79-88. DOI: 10.1016/s0360-3016(98)00266-1. View

Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M . Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2014; 42(5):685-95. DOI: 10.1007/s00259-014-2959-4. View

Carles M, Popp I, Starke M, Mix M, Urbach H, Schimek-Jasch T . FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?. Radiat Oncol. 2021; 16(1):46. PMC: 7931514. DOI: 10.1186/s13014-020-01744-8. View

Kickingereder P, Brugnara G, Hansen M, Nowosielski M, Pfluger I, Schell M . Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. Radiology. 2020; 297(1):164-175. DOI: 10.1148/radiol.2020200978. View

Tsien C, Pugh S, Dicker A, Raizer J, Matuszak M, Lallana E . NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2022; 41(6):1285-1295. PMC: 9940937. DOI: 10.1200/JCO.22.00164. View

10.

Sherriff J, Tamangani J, Senthil L, Cruickshank G, Spooner D, Jones B . Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol. 2013; 86(1022):20120414. PMC: 3608050. DOI: 10.1259/bjr.20120414. View

11.

Andratschke N, Willmann J, Appelt A, Alyamani N, Balermpas P, Baumert B . European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022; 23(10):e469-e478. DOI: 10.1016/S1470-2045(22)00447-8. View

12.

Botros D, Dux H, Price C, Khalafallah A, Mukherjee D . Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review. Neurosurg Rev. 2020; 44(3):1259-1271. DOI: 10.1007/s10143-020-01331-1. View

13.

Brandes A, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R . O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol. 2010; 12(3):283-8. PMC: 2940594. DOI: 10.1093/neuonc/nop050. View

14.

Fokas E, Wacker U, Gross M, Henzel M, Encheva E, Engenhart-Cabillic R . Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?. Strahlenther Onkol. 2009; 185(4):235-40. DOI: 10.1007/s00066-009-1753-x. View

15.

Perry J, Laperriere N, OCallaghan C, Brandes A, Menten J, Phillips C . Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017; 376(11):1027-1037. DOI: 10.1056/NEJMoa1611977. View

16.

Moore-Palhares D, Chen H, Keith J, Wang M, Myrehaug S, Tseng C . Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis. J Neurooncol. 2023; 163(3):541-551. DOI: 10.1007/s11060-023-04340-4. View

17.

Zach L, Guez D, Last D, Daniels D, Grober Y, Nissim O . Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors. PLoS One. 2012; 7(12):e52008. PMC: 3522646. DOI: 10.1371/journal.pone.0052008. View

18.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

19.

Kim E, Yechieli R, Kim J, Mikkelsen T, Kalkanis S, Rock J . Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme. J Neurooncol. 2013; 116(2):291-7. DOI: 10.1007/s11060-013-1290-4. View

20.

Niyazi M, Brada M, Chalmers A, Combs S, Erridge S, Fiorentino A . ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol. 2016; 118(1):35-42. DOI: 10.1016/j.radonc.2015.12.003. View